// App-Quantinova.ai

2777 : BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib.

Researchers

Presenter

  • Hong Gi Lee

Principal Investigators

  • Suzanne Kamel-Reid

  • Jeffrey H. Lipton

Medical Centers

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

  • Toronto, ON, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved